Trial Profile
Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma: a Multicenter, Multinational Retrospective Analysis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pralatrexate (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 01 Dec 2017 New trial record